APA-referens

Verstovsek, S., Passamonti, F., Rambaldi, A., Barosi, G., Rumi, E., Gattoni, E., . . . Vannucchi, A. M. (2017). Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: Long-term phase 2 study results. Blood.

Chicago-stil citat

Verstovsek, Srdan, et al. "Ruxolitinib for Essential Thrombocythemia Refractory to or Intolerant of Hydroxyurea: Long-term Phase 2 Study Results." Blood 2017.

MLA-referens

Verstovsek, Srdan, et al. "Ruxolitinib for Essential Thrombocythemia Refractory to or Intolerant of Hydroxyurea: Long-term Phase 2 Study Results." Blood 2017.

Varning: dessa hänvisningar är inte alltid fullständigt riktiga.